Use of cryptotanshinone

• US 9,233,128 B2
• Filed: 11/06/2013
• Issued: 01/12/2016
• Est. Priority Date: 10/01/2010
• Status: Active Grant

• Current Assignee: Catholic University Industry Academic Cooperation Foundation
• Original Assignee: Catholic University Industry Academic Cooperation Foundation
• Inventors: Shin, Jin Hee, Kim, Kyung Soo, Lee, Il Kyu
• Primary Examiner(s): Claytor, Renee
• Assistant Examiner(s): Paguio Frising, Michelle F
• Application Number:
  US14/073,561
• Publication Number:
  US 20140134138A1
• Time in Patent Office: 797 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: C12N 2501/999 Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2506/1384 from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0654 Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth

Abstract

Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. When the cryptotanshinone is treated to the MSCs, the differentiation into osteoblasts is stimulated, and thus osteogenesis of a patient may be stimulated by directly transplanting the differentiation-induced MSCs to the patient. Accordingly, the composition or osteogenesis stimulator may be used to treat patients having disability requiring stimulation of osteogenesis such as osteoporosis, bone fracture, bone grafting including alveolar bone grafting for implant placement, or other bone defects.

Claims

1. A method for stimulating differentiation of mesenchymal stem cells (MSCs) into osteoblasts in patients having osteoporosis, bone fracture or bone defects, or requiring bone graft, comprising administration to said patients a composition consisting of purified cryptotanshinone, MSCs, and a carrier.

2. The method of claim 1, wherein the cryptotanshinone is included at a concentration of 1 to 50 μ

M.

3. The method of claim 1, wherein the MSCs are obtained from tissue, bone marrow, cord blood, blood, or body fluid.

4. The method of claim 3, wherein the tissue is an adipose tissue.

5. The method of claim 1, wherein the cryptotanshinone is included at a concentration of 1 to 100 μ

M.

6. The method of claim 1, wherein an effective amount of the MSCs is 1×

10⁴ to 1×

10⁶ cells/kg.